Log in to your Inderes Free account to see all free content on this page.
Bioretec
1.865
EUR
-2.61 %
BRETEC
First North Finland
Medical Equipment & Services
Health Care
1,433 following
-2.61%
-0.27%
-14.84%
-36.13%
-30.41%
-22.29%
-18.91%
-36.78%
-
-36.58%
bioretec.com/investors/investors-in-english
Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.
P/E (adj.) (24e)
-8.25
EV/EBIT (adj.) (24e)
-8.18
P/B (24e)
9.56
Dividend yield-% (24e)
-
Target price
2.40 EUR
Recommendation
Accumulate
Updated
15.11.2024
First North Finland
BRETEC
Daily low / high price
1.86 / 1.945
EUR
Market cap
37.93M EUR
Turnover
16.72K EUR
Volume
8.8K
Business risk
Valuation risk
Current
Previous
Analyst
Antti Siltanen
Analyst
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Stephen Industries Inc Oy | 10.9 % | 10.9 % |
| Ilmarinen Mutual Pension Insurance Company | 6.6 % | 6.6 % |
Premium
This content is for our Premium customers only.
Insider Transactions
| Insider | Date | Total value |
|---|---|---|
| Kustaa Poutiainen | 03.01.2024 | 1,273,377EUR |
| Kustaa Poutiainen | 25.10.2023 | 840,000EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 2.0 | 2.9 | 3.9 | 4.2 | 7.0 | 10.6 | 16.1 |
| growth-% | -14.2 % | 33.6 % | 46.9 % | 32.8 % | 6.6 % | 68.5 % | 51.4 % | 51.1 % |
| EBITDA | -2.1 | -2.8 | -2.0 | -2.8 | -4.3 | -3.4 | -0.7 | 1.5 |
| EBIT (adj.) | -1.9 | -2.7 | -2.3 | -3.0 | -4.4 | -3.7 | -1.6 | 0.6 |
| EBIT | -1.9 | -2.7 | -2.3 | -3.0 | -4.4 | -3.7 | -1.6 | 0.6 |
| Profit before taxes | -2.3 | -6.0 | -2.4 | -3.8 | -4.4 | -3.9 | -2.1 | 0.2 |
| Net income | -2.3 | -6.0 | -2.4 | -3.8 | -4.4 | -3.9 | -2.1 | 0.2 |
| EPS (adj.) | -0.02 | -0.43 | -0.17 | -0.20 | -0.23 | -0.20 | -0.11 | 0.01 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -137.8 % | -141.6 % | -68.0 % | -72.6 % | -102.3 % | -48.6 % | -6.1 % | 9.4 % |
| EBIT-% (adj.) | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -105.9 % | -52.2 % | -15.5 % | 3.7 % |
| EBIT-% | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -105.9 % | -52.2 % | -15.5 % | 3.7 % |
| ROE | -4,642.9 % | -211.2 % | -77.8 % | -74.7 % | -73.4 % | -205.8 % | 190.3 % | -10.0 % |
| ROI | -90.4 % | -54.8 % | -46.8 % | -42.9 % | -52.5 % | -61.8 % | -29.6 % | 10.4 % |
Login required
This content is only available for logged in users
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 2.70 | 1.40 | 2.18 | 1.87 | 1.87 | 1.87 | 1.87 | |
| Shares | 150.4 | 14.1 | 14.1 | 19.1 | 19.5 | 19.5 | 19.5 | 19.5 |
| Market cap | 38.1 | 19.8 | 41.7 | 36.4 | 36.4 | 36.4 | 36.4 | |
| Enterprise value | 33.5 | 20.1 | 37.2 | 36.1 | 41.3 | 43.6 | 43.8 | |
| EV/S | - | 16.7 | 6.8 | 9.5 | 8.7 | 5.9 | 4.1 | 2.7 |
| EV/EBITDA | - | - | - | - | - | - | - | 28.8 |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | 72.8 |
| EV/EBIT | - | - | - | - | - | - | - | 72.8 |
| P/E (adj.) | - | - | - | - | - | - | - | 175.4 |
| P/E | - | - | - | - | - | - | - | 175.4 |
| P/B | - | 8.8 | 10.3 | 5.1 | 9.6 | - | - | - |
| P/S | - | 19.0 | 6.7 | 10.7 | 8.7 | 5.2 | 3.4 | 2.3 |
| Dividend yield | ||||||||
| Equity ratio | 35.0 % | 50.3 % | 55.0 % | 77.2 % | 62.2 % | -0.9 % | -40.0 % | -31.9 % |
| Gearing ratio | -16.2 % | -107.1 % | 17.9 % | -54.5 % | -9.1 % | -9,005.9 % | -330.3 % | -372.9 % |
Login required
This content is only available for logged in users
Quarter data
| Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24 | Q4/24e | 2024e | Q1/25e | Q2/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0 | 3.9 | 0.7 | 1.4 | 0.7 | 1.4 | 4.2 | 1.4 | 1.7 |
| EBITDA | -1.8 | -2.8 | -1.1 | -0.8 | -1.4 | -1.0 | -4.3 | -1.0 | -0.9 |
| EBIT | -1.8 | -3.0 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.0 | -0.9 |
| Profit before taxes | -1.7 | -3.8 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.1 | -1.0 |
| Net income | -1.7 | -3.8 | -1.1 | -0.8 | -1.4 | -1.1 | -4.4 | -1.1 | -1.0 |
Login required
This content is only available for logged in users
ShowingAll content types
Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage
Inside information: Bioretec updates its financial targets
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio